NO20051948L - Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens - Google Patents

Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens

Info

Publication number
NO20051948L
NO20051948L NO20051948A NO20051948A NO20051948L NO 20051948 L NO20051948 L NO 20051948L NO 20051948 A NO20051948 A NO 20051948A NO 20051948 A NO20051948 A NO 20051948A NO 20051948 L NO20051948 L NO 20051948L
Authority
NO
Norway
Prior art keywords
leukocytes
compound
imaging
labeled
bind
Prior art date
Application number
NO20051948A
Other languages
English (en)
Norwegian (no)
Inventor
Yoshifumi Shirakami
Ikuya Seki
Takayoshi Kawaguchi
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of NO20051948L publication Critical patent/NO20051948L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20051948A 2002-09-27 2005-04-21 Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens NO20051948L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002282229 2002-09-27
PCT/JP2003/012362 WO2004029080A1 (ja) 2002-09-27 2003-09-26 白血球結合性化合物およびその標識化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
NO20051948L true NO20051948L (no) 2005-06-15

Family

ID=32040529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051948A NO20051948L (no) 2002-09-27 2005-04-21 Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens

Country Status (16)

Country Link
US (1) US7220827B2 (de)
EP (1) EP1548027B1 (de)
JP (1) JP4279781B2 (de)
KR (1) KR100900178B1 (de)
CN (1) CN1684973A (de)
AT (1) ATE382632T1 (de)
AU (1) AU2003266655B2 (de)
CA (1) CA2498826A1 (de)
DE (1) DE60318466T2 (de)
DK (1) DK1548027T3 (de)
ES (1) ES2297268T3 (de)
IL (1) IL167518A (de)
NO (1) NO20051948L (de)
NZ (1) NZ538869A (de)
TW (1) TW200418880A (de)
WO (1) WO2004029080A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
TWI332404B (en) * 2004-03-25 2010-11-01 Nihon Mediphysics Co Ltd Medicinal composition containing peptide improved in water solubility and metal labeling efficacy thereof and medicinal formulation containing metal labeled peptide
EP1904183B1 (de) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmazeutische Zusammensetzung zur Behandlung von Arthrose
KR100630489B1 (ko) 2006-01-10 2006-10-04 주식회사 펩트론 면역반응을 조절하는 펩타이드
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
JP5577245B2 (ja) * 2007-07-11 2014-08-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 画像化での使用を目的としたシードおよびマーカー
SG181899A1 (en) * 2009-12-23 2012-07-30 Sanford Burnham Med Res Inst Methods and compositions related to annexin 1-binding compounds
JP5994971B2 (ja) 2011-03-30 2016-09-21 日本メジフィジックス株式会社 炎症部位集積性化合物、核医学画像診断剤及び標識前駆体
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
NZ314680A (en) 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
WO1997014443A1 (en) * 1995-10-19 1997-04-24 Bracco International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
AU4988900A (en) * 1999-05-05 2000-11-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
CA2399032A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
CA2424643A1 (en) * 2000-10-17 2002-04-25 Trudeau Institute, Inc. Cd38 modulated chemotaxis

Also Published As

Publication number Publication date
EP1548027A4 (de) 2005-11-16
JPWO2004029080A1 (ja) 2006-01-26
CN1684973A (zh) 2005-10-19
US20060057064A1 (en) 2006-03-16
KR20050053691A (ko) 2005-06-08
IL167518A (en) 2009-11-18
DE60318466T2 (de) 2008-09-18
ES2297268T3 (es) 2008-05-01
EP1548027A1 (de) 2005-06-29
DK1548027T3 (da) 2008-05-13
KR100900178B1 (ko) 2009-06-02
AU2003266655B2 (en) 2009-01-08
JP4279781B2 (ja) 2009-06-17
TW200418880A (en) 2004-10-01
DE60318466D1 (de) 2008-02-14
ATE382632T1 (de) 2008-01-15
NZ538869A (en) 2006-09-29
EP1548027B1 (de) 2008-01-02
WO2004029080A1 (ja) 2004-04-08
AU2003266655A1 (en) 2004-04-19
US7220827B2 (en) 2007-05-22
CA2498826A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
Oberhardt et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
US20230241238A1 (en) Bifunctional polypeptides
Hintzen et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex
Taub et al. Alpha and β chemokines induce NK cell migration and enhance NK-mediated cytolysis
NO20051948L (no) Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens
Krukowski et al. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification
BRPI0515589A (pt) polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
Hammer et al. HLA type-independent method to monitor polyoma BK virus-specific CD4+ and CD8+ T-cell immunity
Wright et al. Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor.
AU9399501A (en) Therapeutic antibodies
MY147257A (en) Polypeptides and antibodies
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
DE69403484D1 (de) Prüfungskit
DK1565491T3 (da) Antistoffer, der binder til human magic roundabout (MR), polypeptider og anvendelser deraf til inhibering af angiogenese
Gala-Lopez et al. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation
Deng et al. Optimization of the cytokine secretion assay for human IL‐2 in single and combination assays
West et al. Direct antilymphoma activity of novel, first-generation" antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells
Verdrengh et al. Total abrogation of collagen II-induced arthritis and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist
AU2002321018A1 (en) Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
Kałwak et al. Clinical value of the flow cytometric method for measuring lymphocyte subset activation: spontaneous activation of T-cell subpopulations is associated with acute GvHD
Leifert et al. Radioligand binding assays: Application of [125I] angiotensin II receptor binding
Zeng et al. Selective depletion of activated T cells by recombinant immunotoxin containing anti-CTLA-4 single-chain fragment of variable antibody and N-terminal fragment of perforin
Jeffery et al. Mait cells are enriched in portal tracts and respond to biliary epithelial cells presenting bacterial ligands during liver inflammation
Brandl et al. AB0023 In Vivo Effects of Epratuzumab, A Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-In (HUKI) Mice
Nowakowski et al. A single heptapeptide from a phage display peptide library homes to bone marrow in vivo and binds to primitive murine stem cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application